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ittle is known about the fate of normal human mammary
epithelial cells (HMECs) that lose p53 function in the
context of extracellular matrix (ECM)–derived growth
and polarity signals. Retrovirally mediated expression of
human papillomavirus type 16 (HPV-16) E6 and antisense
oligodeoxynucleotides (ODNs) were used to suppress p53
 
function in HMECs as a model of early breast cancer. p53
 
 
 
HMEC vector controls grew exponentially in reconstituted
ECM (rECM) until day 6 and then underwent growth arrest
on day 7. Ultrastructural examination of day 7 vector controls
revealed acinus-like structures characteristic of normal
mammary epithelium. In contrast, early passage p53
 
 
 
HMEC cells proliferated in rECM until day 6 but then
L
 
underwent apoptosis on day 7. p53
 
 
 
 HMEC-E6 passaged in
non-rECM culture rapidly (8–10 passages), lost sensitivity
to both rECM-induced growth arrest and polarity, and also
developed resistance to rECM-induced apoptosis. Resistance
was associated with altered expression of 
 
 
 
3-integrin.
Treatment of early passage p53
 
 
 
 HMEC-E6 cells with either
 
 
 
3- or 
 
 
 
1-integrin function-blocking antibodies inhibited
rECM-mediated growth arrest and induction of apoptosis.
Our results indicate that suppression of p53 expression in
HMECs by HPV-16 E6 and ODNs may sensitize cells to
rECM-induced apoptosis and suggest a role for the 
 
 
 
3/
 
 
 
1-
heterodimer in mediating apoptosis in HMECs grown in
contact with rECM.
 
Introduction
 
Interactions between extracellular matrix (ECM)* and mam-
mary epithelial cells are critical for the regulation of cellular
proliferation, polarity, and apoptosis (Petersen et al., 1992;
Strange et al., 1992). These normal interactions may be dis-
rupted during breast carcinogenesis (Petersen et al., 1992;
Zutter et al., 1995). It has been observed that although nor-
mal mammary epithelial cells undergo growth arrest in cul-
ture in the presence of reconstituted ECM (rECM), breast
cancer cells and established breast cancer cell lines fail to ex-
hibit similar growth arrest (Petersen et al., 1992). Thus, it is
hypothesized that interaction with ECM may serve to dis-
tinguish the growth patterns of normal and malignant mam-
mary epithelial cells.
The mechanism by which ECM-mediated signal transduc-
tion events might result in changes in gene expression is a sub-
ject of current investigation. It has been shown that rECM
regulates both biomechanical and biochemical signaling
events and conversely that alterations in cell morphology can
alter the response of cells to rECM (Folkman and Moscona,
1978; Roskelley et al., 1994). It is hypothesized that because
malignant cells have an altered response to rECM, ECM sig-
naling pathways may utilize tumor suppressor checkpoints
critical for cellular organization and polarity (Petersen et al.,
1992; Howlett et al., 1994; Weaver et al., 1997).
Integrins are heterodimeric cell surface receptors that link
ECM to structural and functional components within the
cell (Hynes, 1992). There is increasing evidence that inte-
grins are important regulators of normal mammary mor-
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phology, since mammary carcinoma cells frequently demon-
strate atypical patterns of integrin expression including loss,
downregulation, or improper localization (Koukoulis et al.,
1991; Glukhova et al., 1995; Lichtner et al., 1998). In the
normal mammary gland, the 
 
 
 
3/
 
 
 
1 integrin is expressed at
the basal surface of luminal epithelial cells (Koukoulis et al.,
1991; Glukhova et al., 1995). In contrast, invasive breast
carcinomas demonstrate weak staining and redistribution of
the 
 
 
 
3/
 
 
 
1 integrin. Recently, the 
 
 
 
3/
 
 
 
1 integrin has at-
tracted considerable interest, since its function appears to be
versatile. For example, the integrin 
 
 
 
3/
 
 
 
1 functions as a cell
adhesion receptor for laminin-5 (epiligrin), a major ECM
protein present in basement membrane (Xia et al., 1996).
The 
 
 
 
3/
 
 
 
1-integrin is recruited to focal adhesion contacts in
cultured cells and thereby plays an important role in linking
ECM to components of the actin cytoskeleton (Carter et al.,
1990b; Grenz et al., 1993; DiPersio et al., 1995). Integrin
 
 
 
3/
 
 
 
1 is a critical mediator of intracellular adhesion
(Kawano et al., 2001). Studies in keratinocytes suggest that
 
 
 
3/
 
 
 
1 plays a critical role in cell spreading and migration
and promotes gap junctional communication (Carter et al.,
1990b; Xia et al., 1996; DiPersio et al., 1997). Recently, 
 
 
 
3/
 
 
 
1-integrin has been shown to be involved in the initiation
apoptosis (Sato et al., 1999). Taken together, these studies
illustrate the multifaceted role of 
 
 
 
3/
 
 
 
1-integrin in mediat-
ing interactions between ECM and epithelial cells and per-
haps in initiating apoptosis.
Tissue homeostasis is maintained by a dynamic equilib-
rium between cellular proliferation and cell death (Evan and
Littlewood, 1998). Apoptosis is considered to be the pre-
dominant mechanism of cell death and plays a central role in
controlling cell number and eliminating cells sustaining
DNA damage (Ashkenazi and Dixit, 1998). The role of the
tumor suppressor p53 in ECM-induced growth arrest, po-
larity, and apoptosis is unknown. 
 
TP53 
 
is a cell cycle
“checkpoint” gene critical for cell cycle regulation, and it is
functionally inactivated in human cancer at a high frequency
(Hansen and Oren, 1997). Mutations of the 
 
TP53
 
 gene are
detected commonly in breast cancers and are associated with
an increased risk of malignancy (Ashkenazi and Dixit, 1998;
Levesque et al., 1998). Aberrant expression of p53 in mam-
mary epithelial cells may be a biomarker predicting risk for
subsequent breast carcinogenesis. Accumulation of p53 pro-
tein in mammary epithelial cells is detected frequently in
women at high risk for the development of breast cancer
(Fabian et al., 1996) and associated with an increased risk of
Figure 1. Expression of p53 and HPV-16 E6 mRNA and p53 
proteins in HMECs. (a) Expression of endogenous p53 and exoge-
nous HPV-16 E6 mRNA in HMECs. Passage 10 and 18 p53
  HMEC-P 
parental cells (Parental), p53
  HMEC-LXSN controls (LXSN), and 
p53
  HMEC-E6 cells (E6) were analyzed for p53 and HPV-16 E6 
mRNA expression. 10  g of RNA were loaded per lane. 36B4 
served as a loading control. (b) Expression of p53 protein is suppressed 
in p53
  HMEC-E6 cells. Passage 10 and 18 p53
  HMEC-P parental 
cells (Parental), p53
  HMEC-LXSN controls (LXSN), and p53
  
HMEC-E6 cells (E6) were analyzed for p53 protein expression as 
described in Materials and methods. Equal amounts of protein 
lysate were loaded per lane. The protein gel was stained with 
Coomassie blue, and an unknown 45-kD protein band was used 
as a loading control.
Figure 2. Morphologic appearance of early and late passage 
HMECs expressing HPV-16 E6. Electron micrographs of early 
passage (passage 10) p53
  HMEC-LXSN controls (a) and p53
  
HMEC-E6 cells (b) grown in tissue culture for 4 d were similar in 
appearance. (c) Late passage (passage 21) p53
  HMEC-LXSN vector 
control cells were approaching in vitro senescence, were signifi-
cantly larger than early passage cells, and contained increased 
numbers of vesicles. (d) Passage 18 p53
  HMEC-E6 cells were 
similar in appearance (but not identical) to passage 10 cells. 
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progression to breast cancer in women with benign breast
disease (Rohan et al., 1998).
Retrovirally mediated introduction of human papilloma-
virus type 16 (HPV-16) E6 protein into cells provides a
model for the isolated loss of p53 function. The E6 protein
of the cancer-associated HPV-16 binds to p53 and targets it
for degradation through the ubiquitin pathway (Demers
et al., 1996). We employed this approach and antisense
(AS) oligondeoxyucleotides (ODNs) to acutely suppress
p53 function in normal human mammary epithelial cells
(HMECs) in order to model p53 loss in the context of ECM
signaling.
Our results showed that control HMECs expressing p53
underwent rECM-mediated growth arrest and formed a
polarized epithelium. In contrast, HMECs with HPV-16
E6– and ODN-suppressed p53 expression underwent
rECM-induced growth arrest followed by apoptosis. p53
 
 
 
HMEC-E6 cells passaged in non-rECM culture rapidly ac-
quired resistance to rECM-mediated growth arrest, polarity,
and apoptosis after 8 –10 passages in culture. Treatment of
early passage p53
 
  
 
HMEC-E6 cells with either 
 
 
 
3- or 
 
 
 
1-
integrin function-altering antibodies (Abs) blocked rECM-
mediated growth arrest and induction of apoptosis. Obser-
vations in our model system suggest that rECM may play an
important role in the induction of apoptosis in early passage
p53
 
  
 
HMECs via an 
 
 
 
3/
 
 
 
1 signaling pathway.
 
Results
 
p53 protein suppression in HMECs
 
Retrovirally mediated expression of the HPV-16 E6 protein
was used to suppress normal intracellular p53 protein levels
in HMECs. The pLXSN16E6 retroviral vector containing
the coding sequence for HPV-16 E6 viral protein has been
described previously (Demers et al., 1994). Actively dividing
passage 9 AG11132 cells were infected with the retroviral
vector LXSN16E6 or the control vector LXSN, and the in-
fected cells were selected as described in Materials and meth-
ods. All experiments described subsequently were performed
on mass cultures. HMEC-P parental cells, p53
 
  
 
HMEC-
LXSN controls, and p53
 
  
 
HMEC-E6 cells were passaged se-
rially in culture on plastic tissue culture plates. As previously
observed (Seewaldt et al., 1999a,b), p53
 
 
 
 HMEC-LXSN
controls and HMEC-P parental cells exhibited a progressive
increase in doubling time with continued serial passaging
and entered “phase b” growth plateau at about passage 23
(Romanov et al., 2001). In contrast, p53
 
 
 
 HMEC-E6 cells
exhibited an extended lifespan in culture and entered a
growth plateau at passage 40.
Northern blot analysis was performed on p53
 
  
 
HMEC-P
parental cells, p53
 
  
 
HMEC-E6 cells, and p53
 
  
 
HMEC-LXSN
controls (passage 11 and 18) to test for HPV-16 E6 mRNA
expression. Expression of the LTR-initiated E6 mRNA tran-
script was observed in p53
 
  
 
HMEC-E6 cells at passage 11 and
18 but not in parental or vector controls (Fig. 1 a).
Western blots were performed on p53
 
  
 
HMEC-P paren-
tal cells, p53
 
  
 
HMEC-E6 cells, and p53
 
  
 
HMEC-LXSN
controls (passage 11 and 18) to determine the relative levels
of p53 protein expression. Expression of p53 protein was
observed in p53
 
  
 
HMEC-P parental cells and p53
 
  
 
HMEC-
 
LXSN vector controls but was not detectable by Western
analysis in p53
 
  
 
HMEC-E6 cells at either passage 11 or 18
(Fig. 1 b).
 
Cytogenetic analysis of early and late passage p53
 
  
 
and 
p53
 
  
 
HMECs
 
Cytogenetic analysis of p53
 
  
 
HMEC-P parental cells, p53
 
 
 
HMEC-LXSN controls, and early passage p53
 
  
 
HMEC-E6
cells was performed using both spectral karyotyping (SKY)
and DAPI staining to (a) test whether parental and vector
control cells exhibited a normal karyotype and (b) verify that
early passage p53
 
  
 
HMEC-E6 cells did not exhibit specific
karyotypic abnormalities.
38 early passage p53
 
  
 
HMEC-P parental cells (passage 8)
were karyotyped. 35 (92%) metaphase cells had a normal
diploid karyotype. Three cells (8%) exhibited random chro-
mosome loss.
Similarly, 22 early passage p53
 
  
 
HMEC-LXSN control
cells (passage 10) were karyotyped. 20 (91%) p53
 
  
 
HMEC-
LXSN metaphase cells had a normal diploid karyotype. Two
cells (9%) exhibited random chromosome loss.
22 late passage p53
 
  
 
HMEC-LXSN control cells (pas-
sage 17) were karyotyped. 18 (82%) p53
 
  
 
HMEC-LXSN
metaphase cells had a normal diploid karyotype. Three cells
(13%) exhibited random chromosome loss. One cell (5%)
was tetraploid (92 chromosomes). These results are consis-
tent with karyotypes reported for late “phase a” (pregrowth
plateau) HMECs (Romanov et al., 2001).
A total of 21 early passage p53
 
  
 
HMEC-E6 metaphase
cells (passage 10) were karyotyped. Two cells were analyzed
by SKY, and 19 cells were analyzed using inverted and con-
trast-enhanced DAPI staining. The majority of cells (12
Figure 3. rECM-induced growth arrest of early passage p53
  
HMEC-E6 cells and p53
  HMEC-LXSN controls. The mean diameter 
of spheres formed by p53
  HMEC-LXSN controls (passage 10) and 
p53
  HMEC-E6 cells (passage 10) were plotted as a function of days 
in culture. Cells were plated in rECM on day 0 and the diameter of 
growing spherical cell colonies measured with an eye piece 
equipped with micrometer spindle. For both p53
  HMEC-LXSN 
controls and p53
  HMEC-E6 cells, the 20 largest colonies were 
measured at each time point. These data are representative of three 
separate experiments. 
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cells, 57%) had a normal diploid chromosome content,
three cells had random chromosome loss (14%), and the re-
maining cells were aneuploid. In three cells (14%), multiple
losses of whole chromosomes occurred, resulting in the
chromosomes number of 30, 32, and 36, respectively. The
other three cells (14%) were either tetraploid (92 chro-
mosomes) or hypotetraploid (90 and 80 chromosomes).
Only two cells, both near diploid and both studied using
DAPI staining, displayed structural chromosome changes:
inv(20)(p11q13.1) in one cell, and del(X)(p21), dic(14;
19)(q32;q13.4), and a marker chromosome in another.
In contrast to early passage cells, late passage p53
 
 
 
HMEC-E6 (passage 18) were markedly abnormal with nu-
merical and structural chromosome aberrations. A total of 35
metaphase cells were analyzed: 27 using SKY and 8 using in-
verted and contrast-enhanced DAPI staining (Table I).
These results have been published previously (Seewaldt et al.,
2001). No cell had a normal diploid karyotype. The pre-
dominant types of structural changes were deletions, whole
arm translocations, and dicentric chromosomes with break-
points in the pericentromeric and/or telomeric regions. Al-
though a majority of the 35 cells contained complex chro-
mosomal rearrangements, each resistant cell analyzed was
unique. This suggests that chromosome aberrations observed
in the late passage p53
 
  
 
HMEC-E6 cell population resulted
from a generalized event causing karyotypic instability that is
inconsistent with the outgrowth of a mutant clone.
 
Morphologic appearance of early and late passage 
HMECs with HPV-16 E6–suppressed p53 expression
 
Early passage p53
 
 
 
 HMEC-LXSN controls (passage 10) and
p53
 
 
 
 HMEC-E6 cells (passage 10) were similar in appear-
 
Table I. 
 
Karyotype of late passage p53
 
  
 
HMEC-E6 cells
Cell number Karyotype
 
S14 32
 
 
 
2n
 
 
 
,XX,
 
 
 
1,
 
 
 
2,
 
 
 
5,
 
 
 
8,
 
 
 
11,
 
 
 
12,
 
 
 
14,
 
 
 
16,
 
 
 
16,
 
 17, 18, 20, 21,
der(10;21)(q10;q10), 22, mar
S21 35,XX, 2, 3, 5, 6, 7, 8, 11,dic(12;20)(p1?1;p13), 16,del(16)(p11), 18, 19
S24 36, X,t(X;14)(q2?8;q24),r(5),der(6)del(6)(p22)del(6)(q11), 9, 10, 10, 13,
dic(14;21)(q32;q22), 15, 15,der(17;21)(q10;q10), 22
S32 36,XX, 1, 3, 5, 6,del(8)(q13q24), 9, 11, 13, 17, 18, 19
S17 39,X, X, 1,del(3)(p11),der(6;21)(q10;q10),del(8)(q24),del(12)(p13), 15,del(16)(p11), 18, 19, 21
S19 38,XX, 1, 2, 5, 7,dic(9;20)(p11;p13), 15,dic(16;21)(p11;p13), 18
S6 40,XX,del(1)(q3?1), 3,der(6)t(3;6)(?;p11), 10,der(12;16)(q10;q10), 15, 17, 10,
der(?21)t(20;?21)(p11;q11)
S30 41,X,dic(X;12)(q28;p11),del(8)(?p11),der(16;21)(q10;q10),der(15;21)(q10;q10),
dic(17;18)(p11;p11.3), 22
S33 41,XX,dic(5;21)(p1?5;p1?3),dic(12;21)(p1?2;q22),dic(15;17)(p13;q25),dic(16;22)(p11;p1?3),
dic(18;20)(p11.3;q13.?1)
S13 41,XX, 1, 4, 6, 10,dic(12;17)(p13;p1?3),add(16)(p11), 21
S34 42,XX,del(2)(q11),del(9)(q11),del(12)(p1?2),dic(12;16)(p11;q24), 15, 21, 21
S7 44,XX,dic(6;8)(p25;p23), 13,del(17)(p11),der(21;22)(q10;q10)
S9 44,X,dic(X;21)(p22;p1?1),del(2)(q11), der(2), der(2)t(2;16)(?;?q1?3), 16, 17, 19
S2 44,XX,del(7)(q11),trc(7;21;20)(q36;p11q21 22;p13),del(16)(?p11)
S20 44,XX,der(12;16)(q10;q10),dic(20;21)(p13;p1?1)
S26 44,XX,dic(10;17)(q26;p1?1), 12
S28 44,X,dic(X;15)(q11;p11), 16
S29 44,XX, 5,del(16)(p11)
S27 45,XX, 10,der(16)t(10;16)(q11;p11),t(20;20)(q13.1;q13.3)
S16 45,XX, 15,dic(15;15)(q26;p1?3),der(12;16)(q10;q10),der(20)t(18;20)(?q12;p13)
S5 45,XX,dic(14;21)(q3?2;p11), 15,del(16)(p11),del(17)(p11), 21,der(21)t(14;21)(?;?p11)
S18 46,XX,csb(2)(p11),del(9)(q12),del(12)(p13),der(16;21)(q10;q10),dic(20;21)(p13;p13) 
S10 49,XX, 2,dic(3;6)(p26;p25) 2, dic(3;22)(p11;p13), 5, 5,t(5;9)(q35;q34),
dic(6;20)(p25;q13.?1), 7, 8, 10, dic(12;6;19)(p13;?;p13.?3), 13, 14, 15, 16,
der(16)t(13;16)(q1?2;p13)x2, der(17)t(17;19)(p11;?p12), 18,dic(20;20)(p13;q13.3), 21
S15 55,X,t(X8)(q2?8p21), der(X)t(X2)(p22?), 1,del(2)(q11), del(2)(?p11), 3, 4, 5, 5, 7, 7, 9, 11,
 11,dic(12;21)(p13;q22)?dup(12)(p11p13), 13, 14, 16,del(16)(p1?2), 19, 20, 22
S35 61 3n , X, X, X, 1, 2, 3, 3, 4, 5, 7, 7, 8, 9, 12,
der(12)t(X;12)(q21;p13), 14, 15, 16, 20
S1 63 3n ,XXX, 2, 3,der(3)del(3)(p21)del(3)(q2?3), 4,der(6)inv(6)(p25q23)dic(66)(p25q27), 7, 10,
 11, 12,dic(12;22)(p13;p13) 2, 14, 15, 16, 16,dic(20;20)(p13;q13.3), 21,der(21;21)(q10;q10)
S25 84,XXX,del(X)(q13), 3, 5,del(6)(p11), 8, 8,dic(14;16)(p11;p11) 2,dic(17;21)(p13;q22) 2
D1 46,XX,del(16)(p1?1)
D3 43,XX, 15, 19, 20
D10 41,X, X,dic(7;21)(p22;q22), 11,dic(12;?)(p13;?), 15,dic(16;?)(p1?1;?), 20, 21, 22, 2mar
D6 44,XX, 6,der(12;16)(q10;q10)
D9 44,XX,der(16;20)(q10;q10),der(17;21)(q10;q10)
D12 41,XX, 12,add(15)(p11 13), 16,add(17)(p1?1), 20, 21, 21
D14 44,XX, 9,dic(?9;12)(q34;p13),der(16;17)(q10;q10),dic(21;21)(q22;q22)
D2 45,XX,der(12;14)(q10;q10)p53 suppression and rECM-mediated apoptosis | Seewaldt et al. 475
ance (Fig. 2, a and b). Late passage p53
  HMEC-LXSN cells
(passage 21) exhibited morphologic changes characteristic of
senescence including increased cell size and increased cyto-
plasmic vesicles (Fig. 2 c). In contrast, late passage p53
 
HMEC-E6 cells (passage 18) were morphologically similar
(but not identical) to passage 10 cells (Fig. 2 d).
rECM-induced growth arrest of HMECs is not altered 
by the acute expression of HPV-16 E6
Early passage p53
  HMEC-LXSN controls (passage 10) and
p53
  HMEC-E6 cells (passage 10) were grown in prepared
rECM as a single cell suspension. Both p53
  HMEC-LXSN
and p53
  HMEC-E6 cells grew exponentially in rECM un-
til day 6 and then growth arrested on day 6–7 (Fig. 3). They
formed a uniform population of spherical colonies. The
mean diameter of p53
  HMEC-LXSN and p53
  HMEC
colonies on day 7 was 30.5   7.4 and 33  5.5  m, respec-
tively (Fig. 3). There was a decrease in the mean sphere di-
ameter of p53
  HMEC-E6 cells relative to controls on day
9, but this was not statistically significant. These data sug-
gest that the acute suppression of p53 function in HMECs
by HPV-16 E6 alters neither proliferation of cells in contact
with rECM nor rECM-induced growth inhibition as mea-
sured by colony diameter in this in vitro system.
Acute expression of HPV-16 E6 induces apoptosis in 
rECM-growth arrested HMECs in the absence of
p53 expression
EM was performed on early passage rECM growth-arrested
p53
  HMEC-LXSN controls and p53
  HMEC-E6 cells to
test whether suppression of p53 expression by HPV-16 E6
altered the response of HMECs to rECM. p53
  HMEC-
LXSN control cells (passage 10) proliferated in contact with
rECM until day 6 and then underwent rECM-induced
growth arrest on day 6–7.
As observed previously (Seewaldt et al., 1997b), day 7
p53
  HMEC-LXSN cells grown in rECM exhibited an
acinus-like structure consistent with normal nonlactating
mammary glandular epithelium (Fig. 4 a). There was no evi-
dence of apoptosis. Day 14 p53
  HMEC-LXSN cells like-
wise did not exhibit evidence of apoptosis (Fig. 4 b).
In contrast, early passage p53
  HMEC-E6 cells (passage
10) proliferated in rECM until day 6 and then underwent
Figure 4. Early passage p53
  HMEC-E6 
cells undergo apoptosis when cultured 
in contact with rECM starting at 7 d. 
(a and b) Electron micrographs of p53
  
HMEC-LXSN vector control cells (pas-
sage 10) grown in rECM for 7 (a) and 14 
(b) d. p53
  HMEC-LXSN controls formed 
acini-like structures, which demonstrated 
a central lumen (l) consistent with 
nonlactating mammary glandular 
epithelium: (1) nuclei were aligned 
predominantly with the basal surface, 
(2) secretory vesicles (v) were present on 
the luminal surface and not on the basal 
surface, and (3) mitochondria (m) were 
located at the basolateral surface. (c and 
d) p53
  HMEC-E6 cells grown in rECM 
for 6 (c) and 7 (d) d. At 6 d (c), p53
  
HMEC-E6 cells are organized around a 
central lumen, there is cell separation 
(s), nuclei are primarily oriented at the 
basal surface, and vesicles (v) are 
present typically at the luminal surface. 
At 7 d (d), p53
  HMEC-E6 cells demon-
strated evidence of apoptosis including 
(1) nuclear condensation, (2) cell shrink-
age (sh) and separation, (3) margination 
of chromatin (mr), and (4) the presence 
of apoptotic bodies (ap) containing 
cytoplasmic elements.
Figure 5. Expression of p53 protein is suppressed in p53
  
HMEC-AS cells. Passage 10 p53
  HMEC-P parental cells (Parental), 
p53
  HMEC-scrAS controls (scrAS), and p53
  HMEC-AS cells (AS) 
were grown with ( ) or without rECM ( ) and analyzed for p53 
protein expression as described in Materials and methods. Equal 
amounts of protein lysate were loaded per lane. Hybridization with 
Abs to actin serves as the loading control.476 The Journal of Cell Biology | Volume 155, Number 3, 2001
apoptosis on day 7. There was no morphologic evidence of
apoptosis in day 6 rECM cultures (Fig. 4 c). On day 7, 100
early passage p53
  HMEC-E6 cell clusters were surveyed for
the presence or absence of apoptosis. 98 clusters (98%) ex-
hibited morphologic evidence of apoptosis by the following
criteria: (a) nuclear condensation, (b) cell shrinkage and sepa-
ration, (c) margination of chromatin, (d) the presence of ap-
optotic bodies, and (e) mitochondrial condensation (Fig. 4 d).
A second HMEC strain, AG11134, was tested to ensure that
these observations were not HMEC strain specific. Similar to
observations made in HMEC strain AG11132 above, (a)
AG1134-LXSN controls underwent growth arrest and formed
an acinus-like structure in contact with rECM at day 7 (unpub-
lished data), and (b) early passage AG11134-E6 cells exhibited
morphologic evidence of apoptosis at day 7 (unpublished data).
The terminal deoxynucleotidyl transferase (TdT) method
was also used to detect the presence or absence of apoptotic
strand breaks in day 7 rECM culture. The 3 -hydroxyl ter-
mini of apoptotic-induced strand breaks were labeled with
biotin-dUTP by exogenous TdT and were detected in situ
by HRP-conjugated streptavidin. Day 7 rECM growth-
arrested early passage p53
  HMEC-LXSN controls (passage
10) did not demonstrate evidence of apoptosis (unpublished
data). In contrast, early passage day 7 p53
  HMEC-E6–
transduced cells (passage 10) grown in contact with rECM
exhibited apoptotic strand breaks (unpublished data).
These observations indicate that whereas early passage
p53
  HMEC-LXSN controls undergo rECM-induced
growth arrest, early passage p53
  HMEC-E6 cells undergo
rECM-mediated growth arrest on day 6 followed by induc-
tion of apoptosis on day 7. Results from this in vitro model
of rECM-induced apoptosis in HMECs suggest an associa-
tion between HPV-16 E6–induced suppression of p53 func-
tion and the induction of rECM-mediated apoptosis.
Acute suppression of p53 by an AS approach in HMECs 
promotes sensitivity to rECM-mediated apoptosis
Since HPV-16 E6 may have effects other than the suppression
of p53, an AS approach was used to test whether the acute
suppression of p53 function promotes sensitivity to rECM-
mediated apoptosis. p53 protein expression was suppressed
using a p53 AS ODN in HMECs. Western blot analysis dem-
onstrated almost complete suppression of p53 protein expres-
sion in HMECs treated with the p53 AS ODN (p53
 
HMEC-AS) and no suppression of p53 protein expression in
HMECs treated with a scrambled sequence of the p53 AS
ODN (p53
  HMEC–scrambled AS [scrAS]) (Fig. 5).
Figure 6. rECM-induced growth arrest of early passage p53
  
HMEC-AS cells and p53
  HMEC-scrAS controls. The mean diame-
ter of spheres formed by p53
  HMEC-scrAS controls (passage 10) 
and p53
  HMEC-AS cells (passage 10) are plotted as a function of 
days in culture. Cells were plated in rECM on day 0, and the diame-
ter of growing spherical cell colonies was measured with an eye 
piece equipped with micrometer spindle. The 20 largest colonies 
were measured at each time point. These data are representative of 
three separate experiments.
Figure 7. Early passage p53
  HMEC-AS cells undergo apoptosis 
when cultured in contact with rECM starting at 7 d. (a) Electron 
micrographs of p53
  HMEC-scrAS control cells (passage 10) grown 
in rECM for 14 d. p53
  HMEC-LXSN controls formed acini-like 
structures. (b) p53
  HMEC-AS cells grown in rECM for 7 d demon-
strated evidence of apoptosis including (1) nuclear condensation, 
(2) cell shrinkage and separation, (3) margination of chromatin 
(mr), and (4) the presence of apoptotic bodies (ap) containing 
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Consistent with results obtained in early passage p53
 
HMEC-E6 cells, the acute suppression of p53 function by an
AS approach did not alter the ability of p53
  HMEC-AS or
p53
  HMEC-scrAS controls to proliferate in rECM or to
undergo rECM-mediated growth arrest (Fig. 6). Mean diam-
eter of p53
  HMEC-scrAS and p53
  HMEC-AS colonies on
day 7 was 32   4.0 and 31   5.0  m, respectively (Fig. 6).
These data suggest that the acute suppression of p53 function
in HMECs by an AS approach neither alters proliferation of
cells in contact with rECM nor does it alter rECM-induced
growth inhibition as measured by colony diameter.
We tested whether inhibition of p53 protein expression
by an AS approach promoted rECM-mediated apoptosis.
On day 7, 100 early passage p53
  HMEC-AS cell clusters
were surveyed for the presence or absence of apoptosis. Sim-
ilar to early passage p53
  HMEC-E6 cells, p53
  HMEC-AS
cells underwent apoptosis on day 7 (Fig. 7 b). 90 clusters
(90%) exhibited morphologic evidence of apoptosis by the
following criteria: (a) nuclear condensation, (b) cell shrink-
age and separation, (c) margination of chromatin, (d) the
presence of apoptotic bodies, and (e) mitochondrial conden-
sation (Fig. 7 b). In contrast, early passage p53
  HMEC-
scrAS cells did not exhibit morphologic evidence of apop-
tosis on day 7 or 14 (Fig. 7 a; unpublished data). These
observations support the hypothesis that the acute suppres-
sion of p53 function promotes rECM-mediated apoptosis.
Late passage p53
  HMEC-E6 cells acquire resistance to 
rECM-induced growth arrest
Starting at passage 16–18, p53
  HMEC-E6 cells acquired
resistance to rECM-induced growth arrest as evidenced by
continued increase in sphere diameter from day 5 to 9 (Fig.
8). The mean sphere diameter was 37   3  m at day 7 and
48   5  m at day 9. In contrast, passage 17 p53
  HMEC-
LXSN cells exhibited sensitivity to rECM-induced growth
arrest (Fig. 8).
Late passage HMECs with HPV-16 E6-suppressed p53 
function exhibit dysregulated growth and are resistant 
to rECM-induced apoptosis
Late passage p53
  HMEC-LXSN controls (passage 17) and
p53
  HMEC-E6 cells (passage 18) were cultured in rECM.
In contrast to early passage p53
  HMEC-E6 cells, late pas-
sage cells demonstrated disorganized growth and no evidence
of apoptosis at day 7 or 14 (Fig. 9, a and b). Similar to early
passage p53
  HMEC-LXSN vector controls, electron micro-
graphs of late passage controls demonstrated a normal acinus-
like structure without evidence of apoptosis at day 7 (unpub-
lished data) and 14 (Fig. 9 c). Passage 18 p53
  HMEC-E6
cells grown in rECM formed disorganized multilayered irreg-
ularly shaped colonies (Fig. 9, a and b). There was no mor-
phologic evidence of apoptosis in passage 18 p53
  HMEC-
E6 cells grown in rECM. A second HMEC strain AG11134
was tested to confirm that these results were not strain spe-
cific. Late passage AG11134-E6 cells were grown in rECM.
Similar to late passage p53
  HMEC-E6 cells, AG11134-E6
cells formed disorganized aggregates of cells and did not dem-
onstrate evidence of apoptosis (unpublished data). These re-
sults suggest that p53
  HMEC-E6 cells passaged in vitro ac-
quire resistance to rECM-induced apoptosis.
Late passage p53
  HMEC-E6 cells grown in contact 
with rECM lack polarized expression of E-cadherin
Early and late passage p53
  HMEC-LXSN and early passage
p53
  HMEC-E6 cells grown in contact with rECM demon-
strated basolateral expression of E-cadherin, including lateral
staining at cell–cell junctions consistent with a polarized ep-
ithelium (Fig. 10, a–c). 20 cell clusters were surveyed per
data point. These results are similar to what is observed in
normal breast sections and consistent with results obtained
by other investigators when mammary epithelial cells are
grown in contact with rECM (Weaver et al., 1997; Span-
cake et al., 1999). In contrast, late passage p53
  HMEC-E6
cells exhibited punctate dispersed and intracellular staining
consistent with a loss of epithelial polarity (Fig. 10 d). These
results are similar to what is observed in tumorigenic mam-
mary epithelial cells that lack epithelial polarity grown in
rECM (Weaver et al., 1997).
Laminin is critical for the induction of apoptosis in 
early passage p53
  HMEC-E6 cells
To identify the component of rECM that promotes apopto-
sis, early passage p53
  HMEC-E6 cells and p53
  HMEC-
LXSN controls were cultured in growth factor–depleted
Matrigel™, collagen I/IV gels, and collagen I/IV supple-
mented with laminin. Early passage p53
  HMEC-E6 cells
underwent apoptosis when cultured for 7 d in growth fac-
tor–depleted Matrigel™ (Fig. 11 a), suggesting that deple-
tion of growth factors present in the Matrigel™ are not crit-
ical for the induction of apoptosis. Early passage p53
 
HMEC-LXSN controls did not undergo apoptosis when
cultured in growth factor–depleted Matrigel™ (Fig. 11 b).
When early passage p53
  HMEC-E6 cells were cultured in
the presence of collagen I/IV, there was no evidence of apop-
tosis after 7 and 14 d (Fig. 11 c; unpublished data). Like-
wise, early passage p53
  HMEC-LXSN controls did not ex-
hibit evidence of apoptosis when grown in the presence of
Figure 8. Late passage p53
  HMEC-E6 cells are resistant to rECM-
induced growth arrest. The mean diameter of spheres formed by 
late passage p53
  HMEC-LXSN controls (passage 17) and p53
  
HMEC-E6 cells (passage 18) are plotted as a function of days in 
culture as described in Materials and methods. These data are
representative of three separate experiments.478 The Journal of Cell Biology | Volume 155, Number 3, 2001
collagen I/IV (Fig. 11 d). Interestingly, neither early passage
p53
   HMEC-LXSN controls nor p53
   HMEC-E6 cells
formed acinar structures when grown in collage I/IV (Fig.
11, c and d). When human placental laminin was added to
the collagen I/IV gel, both early passage p53
  HMEC-E6
cells and p53
  HMEC-LXSN vector controls developed
branching tubular structures that terminated in spherical ag-
gregates (Fig. 11, e and g). Early passage p53
  HMEC-E6
cells present in both branched and aggregate structures ex-
hibited evidence of apoptosis at 7–10 d (Fig. 11 g). By day
14, no cells were visualized by EM (unpublished data). Like-
wise, early passage p53
  HMEC-E6 cells cultured on a lami-
nin-coated substratum in the presence of a 1:1 dilution of
standard medium to laminin formed similar three-dimen-
sional branching aggregates that also underwent apoptosis
on days 7–10 as determined by EM (unpublished data). In
contrast, early passage p53
  HMEC-LXSN controls grown
in collagen I/IV supplemented with laminin did not exhibit
evidence of apoptosis at 14 d (Fig. 11 h). These observations
suggest a critical role for laminin in the induction of apopto-
sis in p53
  HMEC-E6 cells.
 3-integrin expression is altered in rECM-resistant late 
passage p53
  HMEC-E6 cells
Early and late passage p53
  HMEC-LXSN controls and
p53
  HMEC-E6 cells were tested for  2-,  3-,  6-,  1-,
and  4-integrin expression by immunohistochemistry. All
early and late passage p53
  HMEC-LXSN controls and
early passage p53
  HMEC-E6 cells stained positively for
 2-,  3-, and  1-integrins and very weakly for  6- and  4-
integrins (Fig. 12; unpublished data). Late passage p53
 
HMEC-E6 cells grown in non-rECM culture exhibited a
qualitative decrease in expression of  3-integrin (Fig. 12 d).
Early and late passage p53
  HMEC-LXSN controls and
p53
  HMEC-E6 cells were grown in rECM and tested for
 3- and  1-integrin expression by immunohistochemistry
(clones P1F2 and P4C10, respectively). Early and late pas-
sage p53
  HMEC-LXSN controls and early passage p53
 
HMEC-E6 cells exhibited polarized basal expression of  3-
and  1-integrins (Fig. 13). In contrast, late passage p53
 
HMEC-E6 cells grown in rECM demonstrated disorganized
plasma membrane and cytosolic expression of  3-integrins
(Fig. 13 d). Redistribution of  3-integrins has been seen
Figure 9. Late passage p53
  HMEC-E6 cells are resistant to rECM-
mediated apoptosis. Electron micrographs of late passage p53
  
HMEC-E6 cells grown in rECM for 7 (a) and 14 (b) d and p53
  
HMEC-LXSN controls grown in rECM for 14 d (c). Passage 18 
p53
  HMEC-E6 cells (a and b) grew in disorganized multilayered 
irregularly shaped colonies without morphologic evidence of 
normal cellular polarity or apoptosis. Morphologic evidence of lack 
of polarity included the following: (1) cells were not organized into 
spherical single layer structures, (2) a lumen was not present, and 
(3) secretory vacuoles were distributed randomly throughout the 
cytoplasm. In addition, cells exhibited a prominent nucleolus (nu) 
and disorganized tonofilaments (t) consistent with a less differenti-
ated phenotype. In contrast, late passage p53
  HMEC-LXSN vector 
control cells (passage 17) grown in rECM for 14 d (c) formed 
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previously by other investigators in association with loss of
mammary epithelial cell polarity in rECM culture and is
consistent with these findings (Weaver et al., 1997). Late
passage p53
  HMEC-E6 cells grown in rECM exhibited po-
larized basal  1-integrin expression but had an increase in
the amount of cytosolic expression relative to early passage
cells (Fig. 13 h).
 3- and  1-integrin function-altering Abs inhibit
ECM-induced growth arrest of early passage p53
  and 
p53
  HMEC-E6 cells
Early passage p53
   HMEC-E6 cells (passage 10) were
treated with either  3- or  1-integrin function-altering Abs
or control mouse nonimmune IgG and grown in prepared
rECM as a single cell suspension. As expected, p53
 
HMEC-LXSN controls and p53
  HMEC-E6 cells treated
with nonimmune mouse IgG or  1-integrin–stimulating Ab
(clone B3B11) grew exponentially in rECM until day 6 and
then growth arrested on day 6–7 (Fig. 14 a; unpublished
data), forming a uniform population of spherical colo-
nies. In contrast, p53
  HMEC-LXSN controls and p53
 
HMEC-E6 cells treated with  3- or  1-integrin blocking
Abs (clones P1B5 and JB1A, respectively) did not undergo
growth arrest on day 6–7 and continued to proliferate (Fig.
14, b and c). Mean diameter of control p53
  HMEC-E6
colonies treated with nonspecific mouse IgG on day 7 and 9
was 30   3 and 27   4  m, respectively (Fig. 14 a). Mean
diameter of p53
  HMEC-E6 cells treated with  3- or  1-
integrin blocking Abs on day 9 was 51   5 and 52   4
 m, respectively (Fig. 14 c). p53
  HMEC-LXSN controls
Figure 10. Localization of E-cadherin in p53
  HMEC-LXSN and 
p53
  HMEC-E6 cells using immunofluorescence microscopy. 
Frozen section of early passage p53
  HMEC-LXSN controls (passage 
11) (a), early passage p53
  HMEC-E6 cells (passage 11) (b), late 
passage p53
  HMEC-LXSN controls (passage 16) (c), and late 
passage p53
  HMEC-E6 cells (passage 21) (d) grown in rECM for 
6 d, cryosectioned, and stained with a mAb to E-cadherin as 
described in Materials and methods. E-cadherin was localized at 
the basolateral surface and at points of cell–cell contact in early and 
late passage p53
  HMEC-LXSN cells and in early passage p53
  
HMEC-E6 cells (a–c, arrows). In contrast, late passage p53
  HMEC-
E6 cells showed punctate dispersed membrane and intracellular 
staining (d, arrowheads).
Figure 11. Early passage p53
  HMEC-E6 cells undergo apoptosis when cultured in contact with growth factor–depleted rECM and laminin 
as evidenced by EM. At 7 d (a), passage 11 p53
  HMEC-E6 cells grown in contract with growth factor–depleted rECM demonstrated evidence 
of apoptosis including the following: (1) nuclear condensation, (2) cell shrinkage (sh) and separation, (3) margination of chromatin (mr), and 
(4) the presence of apoptotic bodies (ap) containing cytoplasmic elements. In contrast, passage 11 p53
  HMEC-LXSN controls (b) grown in 
contact with growth factor–depleted rECM did not demonstrate evidence of apoptosis at 14 d. Passage 11 p53
  HMEC-E6 cells (c) and passage 
11 p53
  HMEC-LXSN controls (d) grown in collagen I/IV for 7 d did not demonstrate evidence of apoptosis by morphologic criteria. Light 
micrographs of passage 11 p53
  HMEC-E6 cells grown in collagen I/IV supplemented with laminin (e) exhibited branching structures that 
terminated in spherical cell clusters. Electron micrographs of passage 11 p53
  HMEC-E6 cells grown in collagen I/IV supplemented with 
laminin (g) demonstrated morphologic evidence of apoptosis including cell shrinkage (sh) and nuclear condensation (nu) at 7 d. Light 
micrographs of passage 11 p53
  HMEC-LXSN vector controls grown in collagen supplemented with laminin demonstrated branching 
structures similar to those exhibited by early passage p53
  HMEC-E6 cells (f) but did not demonstrate evidence of apoptosis by EM (h).480 The Journal of Cell Biology | Volume 155, Number 3, 2001
treated with  3- or  1-integrin blocking Abs demonstrated
similar results (Fig. 14 b). These data show that interruption
of   3/ 1-integrin signaling by a blocking Ab inhibits
rECM-mediated growth arrest in both p53
  HMEC-LXSN
controls and early passage p53
  HMEC-E6.
 3- and  1-integrin function-altering Abs inhibit 
rECM-mediated apoptosis of early passage p53
  
HMEC-E6 cells
Early passage p53
  HMEC-E6 cells and early passage p53
 
HMEC-LXSN controls were treated with either  3- or  1-
integrin function-altering Abs or control mouse nonim-
mune IgG and grown in rECM. Electron micrographs of
early passage p53
  HMEC-E6 cells and early passage p53
 
HMEC-LXSN controls treated with either  3- or  1-inte-
grin blocking Abs (clones P1B5 and JB1A, respectively)
demonstrated disorganized cell aggregates without evidence
of apoptosis at day 7 or 14 (Fig. 15; unpublished data).
Early passage p53
  HMEC-E6 cells treated with  1-integrin
blocking Abs also exhibited increased cell–cell separation
(Fig. 15 b). Control p53
  HMEC-E6 cells treated with non-
specific mouse IgG or  1-integrin stimulatory Ab (clone
B3B11) underwent apoptosis on day 7 (unpublished data).
Control p53
  HMEC-LXSN controls treated with nonspecific
mouse IgG did not exhibit apoptosis at day 7 (unpublished
data). These results suggest that  3/ 1-integrin-mediated
signal transduction may be critical for the induction of
apoptosis in early passage p53
  HMEC-E6 cells grown in
contact with rECM.
Discussion
p53 is a critical regulator of cell cycle control, and the high
frequency with which p53 is functionally inactivated in hu-
man malignancy attests to its key role in preventing the
clonal expansion of mutated cells (Hansen and Oren, 1997;
Goetz et al., 2001). Although there is extensive experimental
evidence demonstrating the importance of p53 as a tumor
suppressor and in promoting differentiation, little is known
about the fate of normal human cells that acutely lose p53
function in the context of rECM regulatory signals.
Abnormal p53 expression in benign breast tissue is associ-
ated with the subsequent development of breast cancer and
may represent a very early event in breast carcinogenesis (Fa-
bian et al., 1996; Levesque et al., 1998; Rohan et al., 1998).
Interactions between mammary epithelial cells and ECM
play a critical role in maintaining normal tissue homeostasis
and are likely to be disrupted during breast carcinogenesis.
In this report, we describe an in vitro system for investigat-
ing interactions between HMECs with suppressed p53 pro-
tein expression and rECM as a potential model of early
mammary carcinogenesis.
Figure 12. Late passage p53
  HMEC-
E6 cells exhibit decreased expression of 
integrin  3. Early passage p53
  HMEC-
LXSN controls (passage 10) (a and e), 
early passage p53
  HMEC-E6 cells 
(passage 10) (b and f), late passage p53
  
HMEC-LXSN controls (passage 18) (c 
and g) and late passage p53
  HMEC-E6 
cells (passage 21) (d and h) were grown 
on glass coverslips for 48 h and then 
stained by indirect Immunofluorescence 
with mAb P1F2 against integrin  3 (a–d) 
or with P4C10 against  1-integrin (e–h).
Figure 13. Localization of  3- and 
 1-integrin expression in p53
  HMEC-
LXSN and p53
  HMEC-E6 cells using 
immunofluorescence microscopy. 
Frozen section of early passage p53
  
HMEC-LXSN controls (passage 11) 
(a and e), early passage p53
  HMEC-E6 
cells (passage 11) (b and f), late passage 
p53
  HMEC-LXSN controls (passage 16) 
(c and g), and late passage p53
  HMEC-
E6 cells (passage 21) (d and h) grown in 
rECM for 6 d, cryosectioned, and stained 
with monoclonal Abs to  3- (a–d) and 
 1- (e–h) integrins as described in 
Materials and methods. Integrins  3 and 
 1 were localized to the cell-rECM junction in early and late passage p53
  HMEC-LXSN cells and in early passage p53
  HMEC-E6 cells 
(a–c and e–g). In contrast, late passage p53
  HMEC-E6 cells demonstrated disorganized membrane and cytosolic staining (d).p53 suppression and rECM-mediated apoptosis | Seewaldt et al. 481
Retrovirally mediated expression of HPV-16 E6 and AS
ODNs were used to acutely inhibit p53 protein expression
in HMECs (Figs. 1 and 5). The combination of these ap-
proaches allowed us to utilize both viral and nonviral meth-
ods to suppress p53. We observed that early passage p53
 
HMEC control cells underwent rECM-mediated growth ar-
rest on day 6–7 and formed acinus-like structure (Figs. 3, 4,
and 10). In contrast, early passage p53
  HMEC-E6 cells and
early passage p53
  HMEC-AS cells proliferated until day 6
(Figs. 3, 4, and 6) and then underwent apoptosis on day 7 as
evidenced by EM and by in situ TdT staining (Figs. 4 and 7;
unpublished data). These observations suggest that the acute
suppression of p53 function in HMECs by HPV-16 E6 and
by AS ODNs may promote sensitivity to rECM-induced
apoptosis.
ECM has been shown to provide essential signals for
mammary epithelial cell survival and in their absence cells
undergo apoptosis (Streuli et al., 1991; Strange et al., 1992;
Pullan et al., 1996). The critical relationship between ECM
signaling and p53 expression is highlighted by a recent re-
port that ECM survival signals transduced by focal adhesion
kinase suppress p53-mediated apoptosis (Ilic et al., 1998).
However, there is significant evidence that growth arrest,
differentiation, and survival signals may also promote apop-
Figure 14. Treatment with  3- and  1-
integrin function-altering Abs blocks 
rECM-mediated growth arrest in p53
  
and p53
  HMECs. The mean diameter of 
spheres formed by p53
  HMEC-LXSN 
controls, passage 10 (a and b) and p53
  
HMEC-E6 cells, passage 10 (a and c) 
treated with  3- or  1-integrin function-
altering Abs (b and c) or nonimmune 
mouse IgG (a) is plotted as a function of 
days in culture. Cells were plated in 
rECM on day 0, and the diameter of 
growing spherical cell colonies was 
measured with an eye piece equipped with micrometer spindle. The 20 largest colonies 
were measured at each time point. Both early passage (passage 10) p53
  HMEC-LXSN 
controls and p53
  HMEC-E6 transduced cells treated with nonimmune mouse IgG control 
antiserum proliferated when grown in contact with rECM until day 7 and then underwent 
growth arrest. In contrast, early passage (passage 10) p53
  HMEC-LXSN and p53
  HMEC-E6 
cells treated with  3- and  1-integrin function-altering Abs were resistant to rECM-induced 
growth arrest and continued to proliferate after day 7. These data are representative of three 
separate experiments.
Figure 15. Inhibition of  3- and
 1-integrin signaling blocks induction 
of rECM-mediated apoptosis. Electron 
micrographs of passage 10 p53
  HMEC-
E6 cells (a and b) and passage 10 p53
  
HMEC-LXSN controls (c and d) treated 
with 10  g/ml  3- (a and c) or 20  g/ml 
 1- (b and d) integrin blocking Abs and 
then grown in rECM for 7 d. Cells grew 
in multilayered colonies and did not 
growth arrest at day 6–7. There was no 
morphologic evidence of apoptosis. 
Evidence of lack of polarity included the 
following: (1) cells are not organized 
into spherical single layer structures, (2) 
a lumen was not present, and (3) 
vacuoles and nuclei were randomly 
distributed throughout the cytoplasm. 
Cells treated with  1-integrin blocking 
Abs exhibited cell–cell separation. There 
was no evidence of apoptosis.482 The Journal of Cell Biology | Volume 155, Number 3, 2001
tosis in genetically damaged cells (Seewaldt et al., 1995;
Hong and Sporn, 1997; Mancini et al., 1997; Seewaldt et
al., 1997b).
Our observation that the acute suppression of p53 in
HMECs promotes sensitivity to apoptosis is consistent with
several reports in human and mouse primary fibroblasts that
the acute suppression of p53 results in apoptosis sensitivity
(Hawkins et al., 1996; Wahl et al., 1996; Lanni et al., 1997).
The mechanism by which the acute loss of p53 function
might promote apoptosis is unknown. However, we observe
that immediately after suppression of p53 by HPV-16 E6,
HMECs exhibited a high percentage of tetraploid cells
(14%) and an increased sensitivity to apoptosis. The tumor
suppressor p53 is a critical component of the spindle check-
point that ensures the maintenance of diploidy, and an in-
crease in tetraploidy has been observed in cultured fibro-
blasts from p53-deficient mouse embryo fibroblasts (Cross
et al., 1995). We speculate that it is possible that a loss in the
spindle checkpoint might promote the induction of apopto-
sis when early passage p53
  HMEC cells are exposed to ei-
ther survival or growth arrest signals. Alternatively, p53 also
plays an important role in differentiation, and therefore lack
of p53 might result in cellular disregulation that promotes
cell death. We observe that early passage p53
  HMECs are
sensitive to the induction of apoptosis by other agents that
only promote growth arrest in p53
  HMECs at equimolar
concentrations. For example, we observed that although
tamoxifen promotes G1/S-phase arrest in early passage p53
 
HMEC controls, tamoxifen promoted apoptosis in early
passage p53
  HMECs (Dietze et al., 2001; Seewaldt et al.,
2001). Taken together, these observations provide evidence
that the acute suppression of p53 might promote the induc-
tion of apoptosis when cells are exposed to growth arrest or
survival signals.
Although early passage p53 HMEC-E6 cells underwent
apoptosis when cultured in rECM, late passage cells were re-
sistant to rECM-induced growth arrest, did not exhibit epi-
thelial polarity, and failed to undergo apoptosis (Fig. 9).
Loss of epithelial polarity is based on morphologic appear-
ance by EM and lack of polarized expression of E-cadherin
(Figs. 9 and 10). The development of apoptosis resistance
correlated with the appearance of complex karyotypic ab-
normalities. Unlike early passage cells, late passage p53
 
HMEC-E6 cells continued to proliferate in rECM, formed
multilayered aggregates of cells, and subsequently did not
undergo apoptosis (Figs. 8 and 9). Based upon observations
in our in vitro system, we propose that resistance to rECM-
mediated growth arrest and polarity may promote resistance
to apoptosis.
We investigated which component of rECM may be
proapoptotic. Early passage p53
  HMEC-E6 cells grown in
collagen did not form acinar structures and did not undergo
apoptosis (Fig. 11). Based on these observations, we specu-
late that the presence of collagen I/IV in a 1:1 ratio in our
model system is not sufficient to induce apoptosis nor pro-
mote an acinar structure. When laminin was added to col-
lagen I/IV gels, early passage p53
  HMEC-E6 cells formed
organized branched tubular structures that terminated in
spherical cell clusters and underwent apoptosis (Fig. 11).
Early passage p53
  HMEC-E6 cells cultured in laminin sus-
pension, in the absence of a plastic substratum for adhesion,
formed similar three dimensional structures and likewise un-
derwent apoptosis. This suggests that contact with laminin
is critical for the induction of apoptosis in early passage
p53
  HMEC-E6 cells.
Integrin  3 1 is a critical mediator of intracellular adhe-
sion and an important receptor for laminin-5 (Xia et al.,
1996; Kawano et al., 2001). Recently,  3/ 1-integrin has
been shown to play a potential role in the initiation apopto-
sis in T cells (Sato et al., 1999). Resistance to rECM-medi-
ated apoptosis in late passage p53
  HMEC-E6 cells was as-
sociated with altered expression of  3-integrin (Figs. 12 and
13). Redistribution of  3-integrin has been seen previously
by other investigators in association with loss of mammary
epithelial cell polarity in rECM culture and is consistent
with our findings (Weaver et al., 1997). Treatment of early
passage p53
  HMEC-E6 cells with  3- and  1-integrin
function-altering Abs blocked rECM-mediated growth ar-
rest and inhibited the induction of apoptosis (Figs. 14 and
15). Taken together, these observations suggest an impor-
tant role for  3/ 1 signaling in rECM-mediated growth
regulation and apoptosis.
Previous investigators have tested the ability of  3- and
 1-integrin blocking Abs to mediate growth of breast cell
lines in rECM and in collagen and fibrin gels (Howlett et al.,
1995; Alford et al., 1998). HMT-3522, a nontumorigeneic
breast cell line, demonstrated decreased proliferation in
rECM culture when treated with either the inhibitory anti–
 3-integrin Ab P1B5 or anti– 1-integrin Ab AIIB2 (How-
lett et al., 1995). In contrast, we observed dysregulated prolif-
eration when we treated HMECs with either the inhibitory
anti– 3-integrin Ab P1B5 or anti– 1-integrin Ab JB1A.
The induction of stimulatory or inhibitory functions by Abs
directed to defined integrin subunits has been observed previ-
ously for both anti– 1- and anti– 3-integrin Abs (Lenter et
al., 1993; Driessens et al., 1995; Lichtner et al., 1998) and is
felt to be highly cell type specific. We hypothesize that utili-
zation of nonimmortalized cells with low levels of  6 4-inte-
grin expression may account for differences between our re-
sults and those obtained by Howlett et al. (1995).
In conclusion, we have shown that whereas p53
 
HMEC-LXSN cells undergo growth arrest and form polar-
ized epithelium when grown in contact with rECM, p53
 
HMEC-E6 and p53
  HMEC-AS cells that have acutely
lost p53 function undergo apoptosis. Resistance to rECM-
mediated growth arrest and polarity results in resistance to
rECM-mediated apoptosis and is associated with altered ex-
pression of  3-integrin. Treatment of apoptosis-sensitive
early passage p53
  HMEC-E6 cells with either  3- or  1-
integrin function-altering Abs results in loss of rECM-
mediated growth arrest and resistance to rECM-mediated
apoptosis. We suggest that sensitivity and resistance to
rECM-mediated apoptosis in p53
  HMECs is dependent
on the ability to form a polarized epithelium and may re-
quire  3/ 1-integrin signaling.
Materials and methods
Cell culture and media
HMEC strains AG11132 and AG11134 (M. Stampfer, Lawrence Berkeley
National Laboratory, Berkeley, CA) were purchased from the National In-p53 suppression and rECM-mediated apoptosis | Seewaldt et al. 483
stitute of Aging, Cell Culture Repository (Stampfer, 1985). HMEC strains
AG11132 and AG11134 were established from normal tissue obtained at
reduction mammoplasty, have a limited life span in culture, and fail to di-
vide after  20–25 passages. AG11132 and AG11134 cells exhibit a low
level of estrogen receptor staining characteristic of normal mammary cells.
AG11132 and AG11134 were at passage 8 at the time of receipt. HMECs
were grown in standard medium: mammary epithelial cell basal medium
(Clonetics) supplemented with 4 mg/ml bovine pituitary extract (CC4009;
Clonetics), 5 mg/ml insulin (Upstate Biotechnology), 10 ng/ml EGF (Up-
state Biotechnology), 0.5 mg/ml hydrocortisone (Sigma-Aldrich), 10
 5 M
isoproterenol (Sigma-Aldrich), and 10 mM Hepes buffer (Sigma-Aldrich).
G418 (GIBCO BRL) containing standard medium was prepared by the ad-
dition of 300 mg/ml of G418 to standard medium. Cells were cultured at
37 C in a humidified incubator with 5% CO2/95% air. Mycoplasma test-
ing was performed as reported previously (Seewaldt et al., 1997a).
Retroviral transduction
The LXSN16E6 retroviral vector containing the HPV-16 E6 coding se-
quence (provided by D. Galloway, Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA) has been described previously (Halbert et al., 1991; Dem-
ers et al., 1994). HMECs (passage 9) were plated in four T-75 tissue culture
flasks (Corning) in standard medium and grown to 50% confluency. Trans-
ducing virions from either the PA317-LXSN16E6 or the control PA317-
LXSN (without insert) retroviral producer line were added at a multiplicity
of infection of 1:1 in the presence of 4  g/ml polybrene (Sigma-Aldrich) to
log-phase cells grown in T-75 flasks. The two remaining T-75 flasks were
not infected with virus. After 48 h, the two flasks containing transduced
cells and one flask with untransduced cells were passaged 1:3 (passage 10)
and selected with standard medium containing 300  g/ml G418. Cells
were grown in G418 containing standard medium for 1 wk until 100% of
control untransduced cells were dead. The transduction efficiency was
high during selection, cells were passaged 1:3 at the completion of selec-
tion (passage 11), and cells were maintained in the absence of selection
before immediately proceeding to apoptosis experiments. The fourth flask
of unselected untransduced parental control cells was passaged in parallel
with the selected transduced experimental and vector control cells. Paren-
tal AG11132 cells were designated HMEC-P, transduced cells expressing
the HPV-16E6 construct were designated p53
  HMEC-E6, and vector con-
trol clones were designated p53
  HMEC-LXSN. All cells were maintained
in standard medium after transfection in the absence of G418 selection to
ensure that any chromosomal abnormalities or apoptosis resistance ob-
served was not due to continued exposure to G418. All experiments were
performed on mass cultures.
p53 oligonucleotides
The p53 AS oligonucleotide is an 18-mer targeting the region of the initia-
tion codon (six base pairs immediately before the first and the first four
coding codons): 5 -CGGCTCCTCCATGGCAGT-3 . This AS ODN has
been used previously by several investigators to suppress p53 function (Bi
et al., 1994; Capoulade et al., 2001). The p53 control ODN (5 -CGGCTC-
CTCATGGCAGT-3 ) was chosen to be a scrambled sequence of the AS
ODN to ensure identical nucleotide content and minimize differences po-
tentially attributable to nucleic acid content (Capoulade et al., 2001). In all
ODNs, the first and the last three nucleotides were phosphorothiolate
modified to increase stability in vitro.
Early passage p53
  HMEC-P parental cells were plated in T-75 plates
in standard medium. After allowing 24 h for attachment, cell cultures
were treated for 72 h with either 0.1  M active or scrAS p53 ODNs. The
culture medium was replaced by new standard medium containing fresh
ODNs every 24 h. Western blot analysis was performed to confirm sup-
pression of p53 expression as described below. The resulting film images
were digitized and quantitated using Eastman Kodak, Co. 1D image
analysis software.
rECM culture was as follows: cells were trypsinized, and  10
4 cells
were resuspended in 100  l rECM containing 0.1  M of either active or
p53 scrAS ODN on ice. rECM cultures were prepared as described below.
rECM cultures were overlayed with standard medium containing 0.1  M
of either active or scrambled p53 ODNs. Overlay medium was changed
every 24 h to ensure a fresh supply of ODNs. The diameter of the growing
colonies was determined, and cell colonies were prepared for EM as de-
scribed below. To measure p53 protein expression in cells grown in rECM
culture, colonies were released from the matrix by 60-min incubation at
37 C with dispase (5,000 U/ml caseinolytic activity; Collaborative Re-
search). Released cells were washed once using ice-cold PBS with 5 mM
EDTA and twice with PBS alone. The resulting pellet was tested for p53
protein expression by Western blot analysis as described below.
Western blotting
Preparation of cellular lysates and immunoblotting were performed as pre-
viously described (Seewaldt et al., 1995, 1997b). p53 expression was de-
tected using a 1:100 dilution of mouse anti–human p53 Ab-2 (Oncogene
Research Products) and detected by ECL Western blotting detection re-
agents (Amersham Pharmacia Biotech) as described by the manufacturer.
Northern blot analysis
RNA was extracted with guanidium isothiocyanate and subjected to
Northern blotting in formaldehyde denaturing gels as described previously
(Seewaldt et al., 1995). 10 mg of RNA were loaded per lane. Molecular
probes used in the Northern blot analysis were as follows: the human p53
probe was a 1.9-kb BamH1 fragment (Seewaldt et al., 1997b), and the
36B4 probe was a 700-bp PstI fragment that was used as a loading and
transfer control probe (Seewaldt et al., 1995).
HMEC culture in reconstituted ECM
Mammary epithelial cells were grown in rECM by methods developed by
Bissell and others (Folkman and Moscona, 1978; Howlett et al., 1994;
Roskelley et al., 1994; Seewaldt et al., 1997b). 100  l of rECM (Matrigel™;
Collaborative Research) or growth factor–depleted rECM (growth factor–
reduced Matrigel™; Collaborative Research) were added per well to a 48-
well plate and allowed to gel at 37 C for 20 min. p53
  HMEC-E6–trans-
duced cells and p53
  HMEC-LXSN vector controls were trypsinized,
counted, and pelleted in a sterile microcentrifuge tube. Approximately 10
4
cells were resuspended in 100  l rECM on ice, gently overlaid on the ini-
tial undercoating of ECM, and allowed to gel at 37 C for 20 min. Standard
medium was then added, and wells were inspected to ensure an equal dis-
tribution of cells in each well. Cells were grown for 5–14 d in culture. Me-
dium was changed daily.
For integrin-blocking experiments,  10
4 p53
  HMEC-LXSN vector con-
trol cells (passage 11) or p53
  HMEC-E6 cells (passage 10) were pelleted
and resuspended in 100  l standard medium containing either Abs to  3-
and  1-integrins (Chemicon International) or control nonimmune mouse
IgG for 15 min at room temperature (RT). Final concentration of  3-inte-
grin blocking Ab (CDW496, clone P1B5) was 10  g/ml,  1-integrin block-
ing Ab (CD29, clone JB1A) was 20  g/ml, and  1-integrin stimulatory Ab
(CD29, clone B3B11) was 10  g/ml. 100  l rECM was added to the cell
suspension, gently mixed, and overlaid as described above. 1 ml standard
medium containing the above respective concentration of blocking Ab
was added to each well and changed every other day. Cells were grown
for 5–9 d in rECM culture.
Collagen/laminin morphogenesis assays
Collagen and collagen/laminin gels were prepared by a modification of
methods developed by Alford et al. (1998). Collagen type I (Sigma-Aldrich)
and human placental collagen type IV (Sigma-Aldrich) were solubilized in
0.018 N acetic acid for a final concentration of 3 mg/ml each. Three parts
collagen type I were mixed with one part collagen type IV. The collagen I/IV
solution was neutralized by mixing 8 vol of collagen solution with 1 vol
of sterile PBS and 1 vol of sterile 0.1 M NaOH for a final pH of 7.4. 100  l
of neutralized collagen I/IV solution were added per well to a 48-well
plate and allowed to gel at 37 C for 20 min. Approximately 10
4 early pas-
sage p53
  HMEC-E6 cells and p53
  HMEC-LXSN controls were resus-
pended in 100  l neutralized collagen I/IV solution on ice, gently overlaid
on the initial undercoating of collagen, and allowed to gel at 37 C for 20
min. Standard medium was then added, and wells were inspected to en-
sure an equal distribution of single cells suspended in each well. Cells
were grown for 5–9 d in culture and then prepared for EM as described
previously (Seewaldt et al., 1997b). For collagen/laminin gels, nine parts
collagen I/IV were added to one part human placental laminin (Sigma-
Aldrich), and gels were prepared as above. Laminin cultures were pre-
pared as follows: 48-well plates were coated with 100  l neutralized col-
lagen I/IV solution and baked at 65 C for 24 h. This was repeated three
times. 100  l of human placental laminin were added per well and baked
at 50 C until the laminin solution hardened. This was repeated three times.
Approximately 10
4 early passage p53
  HMEC-E6 cells were suspended in a
1:1 mixture of standard medium and human placental laminin. Cells were
grown for 7 d and prepared for EM as previously described (Seewaldt et
al., 1997b).
Transmission EM
p53
  HMEC-E6 cells and p53
  HMEC-LXSN vector control cells were
grown in contact with rECM as described above, and EM was preformed as
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Cell growth determination in rECM culture
Cell growth was determined by the following criteria: the size of growing
spherical cell colonies was measured with an eye piece equipped with a
micrometer spindle. For both p53
  HMEC-LXSN vector controls and p53
 
HMEC-E6–transduced cells, the 20 largest colonies were measured.
Detection of apoptosis by in situ TUNEL
p53
  HMEC-E6 cells and p53
  HMEC-LXSN vector control cells were
grown in contact with rECM as described above for 5–9 d. Cells were then
fixed in PBS with 10% formalin and embedded in paraffin. Sections were
deparaffinized and quenched in methanol containing 2.1% hydrogen per-
oxide. Antigen retrieval was achieved by placing slides in 10 mM citric
acid at 95 C for 10 min. Nuclear proteins were stripped with 20  g/ml pro-
teinase K, and slides were washed in deionized water. Positive controls
were immersed in DN buffer (30 mM Tris, pH 7.2, 140 mM sodium ca-
codylate, 4 mM magnesium chloride, 0.1 mM DTT) for 5 min at RT and
then incubated with DNAseI (Roche) in DN buffer for 10 min at RT. Nega-
tive controls were treated with 5% FBS. All samples were immersed in TdT
buffer (30 mM Tris, pH 7.2, 140 mM sodium cacodylate, 1.0 mM cobalt
chloride) for 5 min at RT. Sections were covered with TdT/Bio-14-dATP so-
lution (800  l TdT buffer containing 120 U terminal transferase and 50 nM
Bio-14-dATP [GIBCO BRL]), incubated for 1 h at RT, and then the reaction
was terminated with PBS. Sections were blocked with 2% BSA for 10 min
at RT and treated with ABC solution (Elite). Sections were allowed to com-
plex on ice for 30 min, incubated for 30 min at 37 C, and were washed in
PBS. Sections were stained with DAB (2% nickel chloride, 0.1% hydrogen
peroxide) for 3 min at RT and counterstained.
E-cadherin immunostaining
Early and late passage p53
  HMEC-E6 cells and p53
  HMEC-LXSN vector
control cells were grown in rECM as described for 6 d and embedded in
OCT (Miles). Cells were snap frozen, and 5- m sections were obtained.
Sections were fixed in for 30 min at RT with 3.7% formaldehyde in PBS
and were blocked with 0.5% heat-denatured BSA (HD-BSA) in PBS for 1 h
at RT. Cells were then incubated for 30 min with mouse anti–human
E-cadherin Ab (BD Signal Transduction Laboratories), diluted in PBS with
0.5% HD-BSA for 30 min at RT, and then washed six times with PBS at RT.
For Immunofluorescence, cells were incubated with FITC-conjugated goat
anti–mouse Ab at a 1:200 Ab dilution (Santa Cruz Biotechnology, Inc.) in
PBS with 0.5% HD-BSA for 30 min at RT and washed. Sections were
mounted in 30% glycerol in PBS and visualized for immunofluorescence
using a ZEISS LSM 410 fluorescence microscope.
Immunodetection of integrin expression
Early and late passage p53
  HMEC-E6 cells and p53
  HMEC-LXSN vector
control cells were grown on glass coverslips for 48 h in standard medium.
Cells were fixed in for 20 min at RT with 2% formaldehyde in 0.1 M so-
dium cacodylate and 0.1 M sucrose at pH 7.2, permeabilized with 0.1%
Triton X-100 for 10 min at RT, and blocked with 0.5% HD-BSA in PBS for
1 h at RT. Cells were then incubated with a primary Ab diluted in PBS with
0.5% HD-BSA for 1 h at RT and washed six times with PBS at RT. Abs
against integrin subunits  2 (P1H5),  3 (P1F2, P1B5), and  1 (P4C10)
were a gift from William Carter (Fred Hutchinson Cancer Research Center)
and have been described previously (Wayner and Carter, 1987; Wayner et
al., 1988; Carter et al., 1990a,b). Abs against integrin  6 (GoH3) and  4
(3E1) were obtained from Chemicon International. For Immunofluores-
cence, cells were incubated with either FITC-conjugated goat anti–mouse
Ab at a 1:1,500 dilution or goat anti–rat Ab at a 1:4,000 dilution (Dako) in
PBS with 0.5% HD-BSA for 1 h at RT and washed. Sections were mounted
in a solution containing 25 mg/ml of 1,4-diazobicyclo-(2,2,2)octane in
glycerol and visualized for immunofluorescence using a ZEISS LSM 410
fluorescence microscope.
For rECM culture, early and late passage p53
  HMEC-E6 cells and p53
 
HMEC-LXSN vector control cells were grown in contact with rECM for 6 d
in standard medium. Cells were embedded in OCT, snap frozen, and sec-
tioned as described above. Sections were fixed in for 20 min at RT with
2% formaldehyde in 0.1 M sodium cacodylate, 0.1 M sucrose, pH 7.2,
and blocked with 0.5% HD-BSA in PBS for 1 h at RT. Sections were
stained with Abs against integrin subunits  3 (P1F2) and  1 (P4C10) and
visualized as described above.
Cytogenetic analysis of early passage transduced and
parental HMECs
Cultures of p53
  HMEC-P parental cells (passage 10), p53
  HMEC-LXSN
vector controls (passage 10), p53
  HMEC-E6 cells (passage 10), and p53
 
HMEC-E6 cells (passage 18) were checked for sufficient numbers of divid-
ing cells and exposed to colcemid (GIBCO BRL) at a final concentration of
0.01–0.02  g/ml for 2–3 h. Subsequently, the cells were released from
flasks by trypsinization, exposed to hypotonic solution, and fixed as de-
scribed previously (Mrózek et al., 1993). Chromosome preparations were
made, and after appropriate aging slides were subjected to SKY, a method
that enables simultaneous display of all human chromosomes in different
colors (Schröck et al., 1996). Additional slides were also stained with DAPI
(Vector Laboratories) alone. For SKY, the slides were hybridized with the
SKY probe mixture containing combinatorially labeled painting probes for
each of the autosomes and sex chromosomes (Applied Spectral Imaging)
for 42–45 h at 37 C. The hybridization and detection procedures were per-
formed according to the manufacturer’s protocol (Applied Spectral Imag-
ing), and chromosomes were counterstained with DAPI in antifade solu-
tion. The multicolor hybridizations were visualized with the SpectraCube
SD 200 system (Applied Spectral Imaging) mounted on the ZEISS Axioplan
2 epifluorescence microscope using a custom-designed optical filter (SKY-1;
Chroma Technology). The DAPI images of all metaphase cells were ac-
quired using a DAPI-specific optical filter. Spectral analysis and classifi-
cation were performed using SkyView 1.2r visualization and analysis soft-
ware (Applied Spectral Imaging). The assignment of breakpoints in
structural abnormalities was made on comparison of images of SKY classi-
fied chromosomes with the images of the same chromosomes stained with
DAPI that were inverted electronically and contrast enhanced by SkyView
1.2r software. Karyotypic abnormalities were classified according to the
recommendations of the International System for Human Cytogenetic No-
menclature (Mitelman, 1995).
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